| Naveen Hothi, | |
|
1011 Riverside Ave, Roseville, CA 95678-5134 | |
| (707) 393-3457 | |
| Not Available |
| Full Name | Naveen Hothi |
|---|---|
| Gender | Female |
| Speciality | Pharmacist - Ambulatory Care |
| Location | 1011 Riverside Ave, Roseville, California |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1538711809 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 1835P2201X | Pharmacist - Ambulatory Care | 79158 (California) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Naveen Hothi, 1920 Trail Way, Turlock, CA 95382-8655 Ph: (209) 620-2657 | Naveen Hothi, 1011 Riverside Ave, Roseville, CA 95678-5134 Ph: (707) 393-3457 |
News Archive
Research published in the November issue of Anesthesiology describes development of a new Risk Stratification Index (RSI) that allows important clinical outcomes such as length-of-stay and mortality for surgical patients to be accurately compared among hospitals using only publically available billing data. The new risk stratification system is more accurate than existing outcomes measurements such as the Charlson Comorbidity Index (CCI) and the investigators have made it freely available.
While much attention is devoted to reducing medical errors in hospitals, there's a lesser focus on rooting out patient care errors in emergency medical services. To address that gap, the Missouri Center for Patient Safety is developing a program to help medical professionals systematically improve quality and reduce errors during treatment and transport provided by ambulance service providers.
The research, led by Professor Donny Strosberg of Scripps Florida, was published on March 4, 2009, in the Journal of General Virology's advance, online edition, Papers in Press.
Curemark, LLC, a drug research and development company focused on the treatment of neurological diseases, announced that the U.S. Food and Drug Administration has given clearance to Curemark's Investigational New Drug application for a Phase III clinical trial for the use of CM – 4612 in the treatment of attention deficit hyperactivity disorder.
› Verified 1 days ago
Lynn Tuyet Nguyen, PHARM.D Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 1600 Eureka Rd, Roseville, CA 95661 Phone: 916-784-4000 | |
Carol Lynn Schulz, PHARM.D. Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 1600 Eureka Rd, Roseville, CA 95661 Phone: 916-784-4184 | |
Jessica Ng, Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 1600 Eureka Rd, Roseville, CA 95661 Phone: 916-474-6555 | |
Dr. Mina Eskandar, PHARMD Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 1298 Antelope Creek Dr, #521, Roseville, CA 95678 Phone: 518-506-2513 | |
Madison Le, PHARMD Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 9280 Sierra College Blvd, Roseville, CA 95661 Phone: 916-772-5313 | |
Mr. Joseph Chadwick Jacobs, RPH Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 446 Roseville Sq, Roseville, CA 95678 Phone: 916-784-1590 Fax: 916-784-1728 | |
Saimah Arshad, Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 1001 Riverside Ave, Roseville, CA 95678 Phone: 916-486-5256 |